PharmaNeuroBoost initiates a Proof-of-Concept study in Schizophrenia with its second product, PNB02, after securing substantial funding for innovative biomarker research by IWT
PharmaNeuroBoost (PNB) announced that it obtained approval from the Belgian Authorities and from the Central Ethics Committee to initiate a Proof-of-Concept study in patients with chronic schizophrenia. The objectives of this study are to evaluate the effect of PNB02, PNB’s second product in development, on functional magnetic resonance imaging (MRI) of the brain and to evaluate the clinical effect of PNB02 treatment in patients with chronic Schizophrenia who are suffering from residual symptoms.
“Our mission at PNB is to significantly improve the treatment of devastating psychiatric disorders like Schizophrenia that is still insufficient”, says CEO, Erik Buntinx, psychiatrist and inventor of PNB02. “Thanks to the financial support from the Flemish Agency for Innovation by Science and Technology (IWT)”, Buntinx continues, “PNB is provided with the opportunity to perform functional MRI with the objective to identify bio-markers that optimize the development of new drugs”.
“Taking advantage of the innovative neuro-imaging technologies that are available at the University Hospital Gasthuisberg of Leuven, we can measure very precisely the activity in the different parts of the brain in psychiatric patients, and relate it to the clinical effect of new drug candidates”, says Didier de Chaffoy, PhD en Chief Science Officer at PNB, “all in support to the development of better treatments for psychiatric and neurological disorders”.
PNB02 is the second drug development project that is initiated by PNB. PNB01 is at present in phase 3 clinical development in the United States of America and Canada for the treatment of Major Depression.
Other news from the department research and development
